Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200302803> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4200302803 endingPage "S533" @default.
- W4200302803 startingPage "S533" @default.
- W4200302803 abstract "Abstract Background Recent clinical trials have shown weight gain associated with newer antiretrovirals. It is unclear how the nucleoside reverse transcriptase inhibitor backbone affects weight. Recent evidence suggests greater weight gain with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF). However, it is not fully understood whether TDF contributes to weight suppression or weight loss. Methods A systematic search of PubMed, Embase and clinicaltrials.gov was conducted to identify all randomised control trials comparing TDF/FTC or TDF to control in HIV-negative individuals. The primary endpoint included the number of events of ‘5% weight loss’ or ‘abnormal loss of weight’. The Mantel-Haenszel test with random-effects modelling was used to calculate the odds ratio (OR) and 95% confidence intervals (95% CI). Further analyses of gastrointestinal (GI) adverse events (AEs) were undertaken, including the number of reported adverse events of nausea, vomiting, loss of appetite and diarrhoea. Results Seven PrEP trials: PARTNERS, VOICE, TDF-2, Bangkok PrEP, iPrEX, FEM-PrEP and HPTN 084 were included in the analysis of weight loss, with a total sample size of 19,359. One study (HPTN 084) compared TDF/FTC to cabotegravir (CAB). The remaining compared either TDF or TDF/FTC or placebo. HIV-negative individuals taking TDF were more likely to experience weight loss compared to control (OR 1.44 95% CI 1.12 – 1.85 p = 0.005 (table 1)). In a separate analysis of GI AEs, exposure to TDF was also linked to greater odds of vomiting (OR 1.81 95% CI (1.20, 2.73) p < 0.005). There were no increased odds of nausea, diarrhoea, or loss of appetite. Weight loss events in PrEP trials. Conclusion There is evidence in HIV-negative individuals that TDF may be associated weight loss when compared to placebo. Further research should be carried out in HIV positive individuals, and clinical trials of TDF/FTC should publish weight data to widen the evidence base Disclosures All Authors: No reported disclosures" @default.
- W4200302803 created "2021-12-31" @default.
- W4200302803 creator A5057292726 @default.
- W4200302803 creator A5060462160 @default.
- W4200302803 creator A5066826240 @default.
- W4200302803 date "2021-11-01" @default.
- W4200302803 modified "2023-10-16" @default.
- W4200302803 title "882. Use of Tenofovir Disoproxil Fumarate Shows Weight Loss vs Placebo: A Meta-Analysis of 7 Clinical Trials in 19,359 HIV-negative Individuals" @default.
- W4200302803 doi "https://doi.org/10.1093/ofid/ofab466.1077" @default.
- W4200302803 hasPublicationYear "2021" @default.
- W4200302803 type Work @default.
- W4200302803 citedByCount "0" @default.
- W4200302803 crossrefType "journal-article" @default.
- W4200302803 hasAuthorship W4200302803A5057292726 @default.
- W4200302803 hasAuthorship W4200302803A5060462160 @default.
- W4200302803 hasAuthorship W4200302803A5066826240 @default.
- W4200302803 hasBestOaLocation W42003028031 @default.
- W4200302803 hasConcept C126322002 @default.
- W4200302803 hasConcept C142462285 @default.
- W4200302803 hasConcept C142724271 @default.
- W4200302803 hasConcept C156957248 @default.
- W4200302803 hasConcept C197934379 @default.
- W4200302803 hasConcept C203014093 @default.
- W4200302803 hasConcept C204787440 @default.
- W4200302803 hasConcept C27081682 @default.
- W4200302803 hasConcept C2779778239 @default.
- W4200302803 hasConcept C2780852908 @default.
- W4200302803 hasConcept C2911190787 @default.
- W4200302803 hasConcept C2993143319 @default.
- W4200302803 hasConcept C3013748606 @default.
- W4200302803 hasConcept C3017894415 @default.
- W4200302803 hasConcept C44249647 @default.
- W4200302803 hasConcept C511355011 @default.
- W4200302803 hasConcept C544821477 @default.
- W4200302803 hasConcept C71924100 @default.
- W4200302803 hasConceptScore W4200302803C126322002 @default.
- W4200302803 hasConceptScore W4200302803C142462285 @default.
- W4200302803 hasConceptScore W4200302803C142724271 @default.
- W4200302803 hasConceptScore W4200302803C156957248 @default.
- W4200302803 hasConceptScore W4200302803C197934379 @default.
- W4200302803 hasConceptScore W4200302803C203014093 @default.
- W4200302803 hasConceptScore W4200302803C204787440 @default.
- W4200302803 hasConceptScore W4200302803C27081682 @default.
- W4200302803 hasConceptScore W4200302803C2779778239 @default.
- W4200302803 hasConceptScore W4200302803C2780852908 @default.
- W4200302803 hasConceptScore W4200302803C2911190787 @default.
- W4200302803 hasConceptScore W4200302803C2993143319 @default.
- W4200302803 hasConceptScore W4200302803C3013748606 @default.
- W4200302803 hasConceptScore W4200302803C3017894415 @default.
- W4200302803 hasConceptScore W4200302803C44249647 @default.
- W4200302803 hasConceptScore W4200302803C511355011 @default.
- W4200302803 hasConceptScore W4200302803C544821477 @default.
- W4200302803 hasConceptScore W4200302803C71924100 @default.
- W4200302803 hasIssue "Supplement_1" @default.
- W4200302803 hasLocation W42003028031 @default.
- W4200302803 hasOpenAccess W4200302803 @default.
- W4200302803 hasPrimaryLocation W42003028031 @default.
- W4200302803 hasRelatedWork W2108784837 @default.
- W4200302803 hasRelatedWork W2217407134 @default.
- W4200302803 hasRelatedWork W2286371484 @default.
- W4200302803 hasRelatedWork W2318119155 @default.
- W4200302803 hasRelatedWork W2499293218 @default.
- W4200302803 hasRelatedWork W2601864640 @default.
- W4200302803 hasRelatedWork W2943907239 @default.
- W4200302803 hasRelatedWork W4200558563 @default.
- W4200302803 hasRelatedWork W4225724895 @default.
- W4200302803 hasRelatedWork W4291824836 @default.
- W4200302803 hasVolume "8" @default.
- W4200302803 isParatext "false" @default.
- W4200302803 isRetracted "false" @default.
- W4200302803 workType "article" @default.